Evidence map›Paper›PMID 29770197›Full record

ArticleF1000Research2017

Case Report: Treatment of systemic mastocytosis with sunitinib.

Gerhard J Molderings, Lawrence B Afrin, Hans-Jörg Hertfelder, Stefan Brettner

Abstract read
In one paragraph

Article in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Phase II Study of Sunitinib in Tumors WithJCO precision oncology · 2024
    Trial
  2. Avapritinib in the Treatment of Systemic Mastocytosis: an Update.Current hematologic malignancy reports · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gerhard J MolderingsInstitute of Human Genetics, University Hospital Bonn, Bonn, D-53127, Germany.ORCID https://orcid.org/0000-0002-9005-2749
Lawrence B AfrinArmonk Integrative Medicine, Armonk, NY, 10504, USA.
Hans-Jörg HertfelderInstitute of Experimental Haematology & Transfusion Medicine, University Hospital of Bonn, Bonn, D-53127, Germany.
Stefan BrettnerDepartment of Oncology, Hematology and Palliative Care, Kreiskrankenhaus Waldbröl, Waldbröl, D-51545, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mast cell activation disease typically presents as chronic multisystem polymorbidity of generally inflammatory ± allergic theme.  Presently, treatment of the rare, cytoproliferative variant systemic mastocytosis employs empirically selected therapies to impede mast cell mediator production and action and, when necessary, inhibition of proliferation. Some tyrosine kinase inhibitors (TKIs) have been used successfully in uncommon cases of systemic mastocytosis not bearing that disease's usual imatinib-resistant KIT

Indexed as

mast cellsunitinibsystemic mast cell activation diseasesystemic mastocytosistyrosine kinase inhibitors

Identifiers

PMID29770197
PMCPMC5946163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.